Bortezomib - BioXcel

Drug Profile

Bortezomib - BioXcel

Alternative Names: BXCL 101

Latest Information Update: 11 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioXcel Corporation
  • Class Antineoplastics; Antirheumatics; Boronic acids; Pyrazines; Small molecules
  • Mechanism of Action Apoprotein stimulants; Immunomodulators; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neurofibromatosis 2
  • New Molecular Entity No
  • Available For Licensing Yes - Neurofibromatosis 2

Highest Development Phases

  • Clinical Phase Unknown Neurofibromatosis 2

Most Recent Events

  • 11 May 2017 Chemical structure information added
  • 17 Apr 2017 Bortezomib - BioXcel is available for licensing as of 17 Apr 2017. (BioXcel website, April 2017)
  • 13 Sep 2016 Clinical trials in Neurofibromatosis 2 in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top